Literature DB >> 18414781

Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney.

Ken Ogasawara1, Tomohiro Terada1, Hideyuki Motohashi1, Jun-Ichi Asaka1, Masayo Aoki1, Toshiya Katsura1, Tomomi Kamba2, Osamu Ogawa2, Ken-Ichi Inui3.   

Abstract

Organic cation transporters (OCTs) and organic anion transporters (OATs) (SLC22A family) play crucial roles in the renal secretion of various drugs. Messengar ribonucleic acid (mRNA) expression of transporters can be a key factor regulating interindividual differences in drug pharmacokinetics. However, the source of variations in mRNA levels of transporters is unclear. In this study, we focused on single nucleotide polymorphisms (SNP) in the promoter region [regulatory SNPs (rSNPs)] as candidates for the factor regulating mRNA levels of SLC22A. We sequenced the promoter regions of OCT2 and OAT1-4 in 63 patients and investigated the effects of the identified rSNPs on transcriptional activities and mRNA expression. In the OCT2 promoter region, one deletion polymorphism (-578_-576delAAG) was identified; -578_-576delAAG significantly reduced OCT2 promoter activity (p < 0.05), and carriers of -578_-576delAAG tend to have lower OCT2 mRNA levels, but the difference is not significant. There was no rSNP in the OAT1 and OAT2 genes. The five rSNPs of OAT3 and one rSNP of OAT4 were unlikely to influence mRNA expression and promoter activity. This is the first study to investigate the influences of rSNPs on mRNA expression of SLC22A in the kidney and to identify a regulatory polymorphism affecting OCT2 promoter activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414781     DOI: 10.1007/s10038-008-0288-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  12 in total

Review 1.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

Review 2.  Pharmacogenetic studies update in type 2 diabetes mellitus.

Authors:  Shalini Singh; Kauser Usman; Monisha Banerjee
Journal:  World J Diabetes       Date:  2016-08-10

3.  Organic Cation Transporter 2 (OCT2/SLC22A2) Gene Variation in the South African Bantu-Speaking Population and Functional Promoter Variants.

Authors:  Nina C Wilson; Ananyo Choudhury; Nadia Carstens; Demetra Mavri-Damelin
Journal:  OMICS       Date:  2017-02-16

Review 4.  Clinical pharmacokinetics of metformin.

Authors:  Garry G Graham; Jeroen Punt; Manit Arora; Richard O Day; Matthew P Doogue; Janna K Duong; Timothy J Furlong; Jerry R Greenfield; Louise C Greenup; Carl M Kirkpatrick; John E Ray; Peter Timmins; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

5.  Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.

Authors:  Wolin Hou; Dandan Zhang; Wei Lu; Taishan Zheng; Lili Wan; Qing Li; Yuqian Bao; Fang Liu; Weiping Jia
Journal:  Mol Diagn Ther       Date:  2015-02       Impact factor: 4.074

6.  Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4).

Authors:  Fanfan Zhou; Ling Zhu; Pei H Cui; W Bret Church; Michael Murray
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

7.  Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5).

Authors:  Harunobu Tahara; Sook Wah Yee; Thomas J Urban; Stephanie Hesselson; Richard A Castro; Michiko Kawamoto; Doug Stryke; Susan J Johns; Thomas E Ferrin; Pui-Yan Kwok; Kathleen M Giacomini
Journal:  J Pharmacol Exp Ther       Date:  2009-01-13       Impact factor: 4.030

8.  Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.

Authors:  Ying Chen; Shuanglian Li; Chaline Brown; Stephen Cheatham; Richard A Castro; Maya K Leabman; Thomas J Urban; Ligong Chen; Sook Wah Yee; Ji Ha Choi; Yong Huang; Claire M Brett; Esteban G Burchard; Kathleen M Giacomini
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

9.  Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Authors:  Sook Wah Yee; Anh Nguyet Nguyen; Chaline Brown; Radojka M Savic; Youcai Zhang; Richard A Castro; Cheryl D Cropp; Ji Ha Choi; Diment Singh; Harunobu Tahara; Sophie L Stocker; Yong Huang; Claire M Brett; Kathleen M Giacomini
Journal:  J Pharm Sci       Date:  2013-05-06       Impact factor: 3.534

Review 10.  Analytical methods for inferring functional effects of single base pair substitutions in human cancers.

Authors:  William Lee; Peng Yue; Zemin Zhang
Journal:  Hum Genet       Date:  2009-05-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.